Clinical Observation of Sixty-eight Patients with Hyperlipidemia Treated by Shenling Baizhu Powder

ZHANG Xuan-ming; YE Dan; ZHANG Hong-xia; YANG Bai-jing

doi:10.13422/j.cnki.syfjx.2015120158

您当前的位置：

首页 >

文章列表页 >

Clinical Observation of Sixty-eight Patients with Hyperlipidemia Treated by Shenling Baizhu Powder

更新时间：2024-01-04

- Clinical Observation of Sixty-eight Patients with Hyperlipidemia Treated by Shenling Baizhu Powder
- Chinese Journal of Experimental Traditional Medical Formulae Vol. 21, Issue 12, Pages: 158-161(2015)
- 作者机构：
- 作者简介：
- 基金信息：
- DOI：10.13422/j.cnki.syfjx.2015120158
  CLC： R259
- Published：2015
- 稿件说明：
移动端阅览
ZHANG Xuan-ming, YE Dan, ZHANG Hong-xia, et al. Clinical Observation of Sixty-eight Patients with Hyperlipidemia Treated by Shenling Baizhu Powder[J]. Chinese journal of experimental traditional medical formulae, 2015, 21(12): 158-161.
DOI：

ZHANG Xuan-ming, YE Dan, ZHANG Hong-xia, et al. Clinical Observation of Sixty-eight Patients with Hyperlipidemia Treated by Shenling Baizhu Powder[J]. Chinese journal of experimental traditional medical formulae, 2015, 21(12): 158-161. DOI： 10.13422/j.cnki.syfjx.2015120158.

摘要

目的: 观察参苓白术散加味治疗高脂血症的临床疗效及安全性。方法: 将136例高脂血症患者随机分为治疗组(68例)和对照组(68例)。治疗组给予参苓白术散加味治疗

对照组给予西药辛伐他汀片治疗

两组连续治疗8周

检测治疗前后两组患者临床疗效、血脂水平、血液流变学变化和不良反应。结果: ①总有效率治疗组86.8%

对照组83.8%。两组比较无显著性差异。②中医证候疗效总有效率治疗组为89.7%

对照组为 54.4%

两组比较有非常显著性意义(P<0.01)。 ③两组疗后总胆固醇(TC)

甘油三酯(TG)

高密度脂蛋白胆固醇(HDL-C)

低密度脂蛋白胆固醇(LDL-C)较疗前有非常显著或显著改变(P<0.01

P<0.05);治疗组降低TG[治疗后治疗组与对照组分别为(1.86±0.51)

(2.54±0.69) mmol·L-1]

升高HDL-C[治疗组与对照组分别为(1.74±0.52)

(1.19±0.40) mmol·L-1]作用优于对照组(P<0.05)。④两组疗后全血黏度高切、全血黏度低切、血浆黏度和红细胞压积较疗前有显著降低(P<0.05)

两组比较无显著性差异。⑤治疗组未见不良反应。结论: 参苓白术散加味治疗高脂血症总有效率与辛伐他汀相当

降低TG和升高HDL-C优于对照组

能缓解患者中医证候

同时改善患者血液流变学

且无明显的不良反应。

Abstract

Objective: The study aimed to observe the clinical efficacy and safety of Shenling Baizhu powder on patients with hyperlipidemia. Method: In this study

136 patients with hyperlipidemia were randomly divided into the treatment group(referred to as Shenling Baizhu powder treatment) and the control group(referred to as the western medicine simvastatin treatment)with 68 patients in each group. Each group was treated for 8 weeks

and the clinical effect

lipid changes

blood rheology changes and side-effects before and after treatment were observed. Result: ① The total effective rate of the treatment group was 86.8%

while it was 83.8% in the control group. With no significant difference. ② The total effective rate of traditional Chinese medicine(TCM)syndrome in treatment group was 89.7%

while it was 54.4% in control group

with significant difference between two groups (P<0.01). ③There were significant change in the total cholesterol(TC)

triglyceride(TG)

high density lipoprotein cholesterol(HDL-C) and low density lipoprotein cholesterol(LDL-C)between the two groups after treatment (P<0.01

P<0.05). The effects of reducing TG in the treatment group[the treatment group was (1.86± 0.51) mol·L-1

and the control group was(2.54±0.69) mmol·L-1]and elevating HDL-C[The treatment group was (1.74±0.52)

and the control group was (1.19±0.40) mmol·L-1]were better than those in control group after treatment (P<0.05).④ In the two groups

the whole blood high shear viscosity

whole blood low shear viscosity

plasma viscosity and erythrocyte deposited were all had significantly lower than before treatment (P<0.05)

but with no significant difference between the two groups.⑤No side-effects were observed in treatment group. Conclusion: The total effective rate of Shenling Baizhu powder is equivalent to simvastatin in treating hyperlipidemia

but better than control group in reducing TG and elevating HDL-C is

which can alleviate the syndromes of patients

improve the blood rheology

with no side-effects.

关键词

Keywords

references

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Clinical Efficacy of Zhuyuwan in Treatment of Hyperlipidemia with Syndrome of Phlegm Turbidity and Obstruction

Zhuyuwan in Treatment of Hyperlipidemia Complicated with Carotid Atherosclerosis： A Randomized Controlled Trial

Mechanism of Wendantang in Intervention of ApoE^-/- Hyperlipidemic Mice Based on Liver Metabolomics

Polygonati Odorati Rhizoma Polysaccharides Ameliorate Hyperlipidemia in Mice by Regulating Gut Microbiota

Wendantang Regulates Energy Metabolism in Treatment of Myocardial Ischemia via SIRT3/PGC-1α Pathway

Related Author

YANG Lele

LUO Danmei

CHEN Jiao

ZHANG Xiaobo

SONG Wei

ZHU Wenyu

ZHOU Xin

LI Xueping

Related Institution

Chengdu University of TCM

Hospital of Chengdu University of Traditional Chinese Medicine （TCM）

Hospital of Chengdu University of TCM

Chengdu University of Traditional Chinese Medicine（TCM）

Research Center for Differentiation and Development of Traditional Chinese Medicine （TCM） Basic Theory/Jiangxi Province Key Laboratory of Biological Etiologies of TCM/First-Level Discipline Platform of Chinese and Western Integrative Medicine/Experimental Animal and Scientific Technology Center of Jiangxi University of Chinese Medicine/School of Pharmacy， Jiangxi University of Chinese Medicine

AI问答

Postal code：100700
Tel：010-84076882 Email：syfjx_2010@188.com
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备11006657号-10 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰